Results 261 – 269 of 269 for Enhertu (0.05 seconds)

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial

biologically diverse breast cancer tumour environment. With Enhertu (trastuzumab deruxtecan), a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are ...

Serbia

akalabrutinib Daxas® 500 mcg film tableta roflumilast Enhertu 100 mg prašak za koncentrat za rastvor za infuziju trastuzumab derukstekan Faslodex® 250 ...

New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings

(gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) and Datroway in collaboration with Daiichi Sankyo; ...

Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 trial

biologically diverse breast cancer tumour environment. With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), ...

All medicines

Enhertu trastuzumab deruxtecan

Croatia

obložene tablete dapagliflozin propandiolhidrat #Enhertu 100 mg prašak za koncentrat za otopinu za infuziju trastuzumab derukstekan Etcamah 75 mg ...

Externally sponsored scientific research

considered if not overlapping with existing portfolio Enhertu / Trastuzumab deruxtecan (DS-8201/T-DXd) Make a submission HER2-targeting Antibody ...

Greece

ENHERTU® (TRASTUZUMAB DERUXTECAN)

Results and presentations

Enhertu and breast cancer

Previous 17 18 19 20 21 22 23 24 25 26 27 Next